Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE. Vanover KE, et al. Among authors: burstein es. J Pharmacol Exp Ther. 2006 May;317(2):910-8. doi: 10.1124/jpet.105.097006. Epub 2006 Feb 9. J Pharmacol Exp Ther. 2006. PMID: 16469866
Pharmacology of polymorphic variants of the human 5-HT1A receptor.
Del Tredici AL, Schiffer HH, Burstein ES, Lameh J, Mohell N, Hacksell U, Brann MR, Weiner DM. Del Tredici AL, et al. Among authors: burstein es. Biochem Pharmacol. 2004 Feb 1;67(3):479-90. doi: 10.1016/j.bcp.2003.09.030. Biochem Pharmacol. 2004. PMID: 15037200
Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation.
Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, Davis RE, Brann MR, Burstein ES. Spalding TA, et al. Among authors: burstein es. Mol Pharmacol. 2006 Dec;70(6):1974-83. doi: 10.1124/mol.106.024901. Epub 2006 Sep 7. Mol Pharmacol. 2006. PMID: 16959945
Pharmacology of N-desmethylclozapine.
Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW. Lameh J, et al. Among authors: burstein es. Pharmacol Ther. 2007 Aug;115(2):223-31. doi: 10.1016/j.pharmthera.2007.05.004. Epub 2007 May 21. Pharmacol Ther. 2007. PMID: 17583355 Review.
Identification of novel selective V2 receptor non-peptide agonists.
Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F. Del Tredici AL, et al. Among authors: burstein es. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12. Biochem Pharmacol. 2008. PMID: 18761325
5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR. Weiner DM, et al. Among authors: burstein es. J Pharmacol Exp Ther. 2001 Oct;299(1):268-76. J Pharmacol Exp Ther. 2001. PMID: 11561089
Discovery of an ectopic activation site on the M(1) muscarinic receptor.
Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR. Spalding TA, et al. Among authors: burstein es. Mol Pharmacol. 2002 Jun;61(6):1297-302. doi: 10.1124/mol.61.6.1297. Mol Pharmacol. 2002. PMID: 12021390
99 results